Zhao Bojia

Introduction

Attorney Zhao Bojia is an equity partner at Jingtian & Gongcheng. With more than a decade of extensive practical experience in the life sciences and healthcare and a deep understanding of pharmaceutical policies, she has been the legal advisor in handling numerous landmark M&A projects and representative “first-of-its-kind” projects in various sectors of life sciences and healthcare.

These cases include one of the largest M&A deals in the Chinese healthcare services sector in 2022 – China General Technology (Group) Holding’s acquisition of Gem Flower Healthcare Investment Holdings. The project was honored among China Business Law Journal’s deals of the year 2022. It is one of the largest controlling cross-border M&A deals in the Chinese pharmaceutical distribution sector, one of the largest cross-border M&A deals in the healthcare services sector, the first franchise operation of a public hospital in China, a project of the largest US chain of medical groups establishing its presence in China, and a collaboration between China Meheco Group and Pfizer on the exclusive operating rights for COVID-19 treatment drugs in China. These outstanding achievements have earned Zhao recognition from prestigious international ranking institutions such as

Chambers and Partners, The Legal 500, LEGALBAN, and ALB, securing almost all the top positions in the legal service rankings related to life sciences and health.

Over the years, Zhao has accumulated rich practical experience in M&A, financing, and IPO projects in various sectors of healthcare. She is capable of providing end-to-end legal services, including due diligence, design of deal structure, drafting transaction documents, assisting in negotiations, and assisting settlements.

She offers specialised policy research and interpretation services to clients with her precise judgment and in-depth understanding of national healthcare policies. The service assists clients in deepening their understanding of relevant policy provisions within specific sectors of life sciences and healthcare and provides insights and interpretations for future policy directions, receiving unanimous praises from them.